Recent weeks have seen notable developments in the area of disease-modifying therapies for Alzheimer’s disease. On 15 April, the European Commission approved lecanemab, the first treatment authorised by the European Medicines Agency (EMA) to slow progression in early-stage Alzheimer’s. The approval followed a complex regulatory process, including an appeal. It comes shortly after the EMA declined to authorise donanemab, due to concerns about its risks. The Alzheimer Society of Ireland (ASI)’s response was featured in national media. Dr Laura O'Philbin (pictured), The ASI’s Research & Policy Manager, contributed to the discussion, appearing on “Newstalk” radio and writing a letter to the editor of The Irish Times which was published. In her letter, she emphasised the need to prioritise the perspectives of people living with dementia and their families in the risk-benefit debate. A longer version of her letter was published as an opinion piece in The Irish Examiner. It is available to read here:
https://www.irishexaminer.com/opinion/commentanalysis/arid-41614852.html
